Bioton S.A. (BIO) - Total Liabilities
Based on the latest financial reports, Bioton S.A. (BIO) has total liabilities worth zł170.59 Million PLN (≈ $46.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioton S.A. - Total Liabilities Trend (2005–2025)
This chart illustrates how Bioton S.A.'s total liabilities have evolved over time, based on quarterly financial data. See Bioton S.A. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Bioton S.A. Competitors by Total Liabilities
The table below lists competitors of Bioton S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WIZ CORP Inc
KQ:038620
|
Korea | ₩18.70 Billion |
|
Suwen Tekstil Sanayi Pazarlama AS
IS:SUWEN
|
Turkey | TL1.83 Billion |
|
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
|
Brazil | R$112.60 Million |
|
Paseco Co. Ltd
KQ:037070
|
Korea | ₩33.66 Billion |
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
Taiwan | NT$1.02 Billion |
|
Da Ming International Holdings Limited
F:DM7
|
Germany | €9.59 Billion |
|
Seer Inc
NASDAQ:SEER
|
USA | $30.65 Million |
|
Netas Telekomunikasyon AS
IS:NETAS
|
Turkey | TL8.17 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Bioton S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioton S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioton S.A. (2005–2025)
The table below shows the annual total liabilities of Bioton S.A. from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł170.59 Million ≈ $46.95 Million |
-16.21% |
| 2024-12-31 | zł203.59 Million ≈ $56.03 Million |
-5.69% |
| 2023-12-31 | zł215.87 Million ≈ $59.41 Million |
+5.68% |
| 2022-12-31 | zł204.27 Million ≈ $56.22 Million |
-15.75% |
| 2021-12-31 | zł242.45 Million ≈ $66.73 Million |
-2.03% |
| 2020-12-31 | zł247.46 Million ≈ $68.11 Million |
-17.35% |
| 2019-12-31 | zł299.42 Million ≈ $82.40 Million |
+0.74% |
| 2018-12-31 | zł297.23 Million ≈ $81.80 Million |
-19.39% |
| 2017-12-31 | zł368.72 Million ≈ $101.48 Million |
-23.40% |
| 2016-12-31 | zł481.36 Million ≈ $132.48 Million |
+8.56% |
| 2015-12-31 | zł443.41 Million ≈ $122.03 Million |
-12.77% |
| 2014-12-31 | zł508.32 Million ≈ $139.90 Million |
+0.52% |
| 2013-12-31 | zł505.69 Million ≈ $139.17 Million |
-12.62% |
| 2012-12-31 | zł578.69 Million ≈ $159.26 Million |
-9.53% |
| 2011-12-31 | zł639.67 Million ≈ $176.05 Million |
+55.34% |
| 2010-12-31 | zł411.78 Million ≈ $113.33 Million |
-21.54% |
| 2009-12-31 | zł524.85 Million ≈ $144.45 Million |
-36.54% |
| 2008-12-31 | zł827.09 Million ≈ $227.63 Million |
+25.44% |
| 2007-12-31 | zł659.36 Million ≈ $181.47 Million |
+259.27% |
| 2006-12-31 | zł183.53 Million ≈ $50.51 Million |
+78.69% |
| 2005-12-31 | zł102.70 Million ≈ $28.27 Million |
-- |
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more